CryoLife submits corrective plan to FDA:
This article was originally published in Clinica
CryoLife has submitted its corrective action plan to the US FDA outlining proposed steps to validate the company's tissue processing procedures. It is currently processing tissue for use in medically urgent cases under the terms of a 45-working-day interim agreement signed on September 6 with the FDA, which also stipulated that the company draw up the action plan in collaboration with a third-party consultant or reviewer within 30 days. The agency will now decide whether to allow CryoLife to return to the market and release tissue subject to the original recall order of August 13 (see Clinica No 1027, p 17). The company's share price closed up 25% at $2.69.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.